Total Payments
$270,304
2024 Payments
$5,790
Companies
21
Transactions
73
Medicare Patients
1,396
Medicare Billing
$386,122
Payment Breakdown by Category
Research$196,664 (72.8%)
Consulting$57,401 (21.2%)
Other$11,262 (4.2%)
Travel$2,548 (0.9%)
Food & Beverage$2,431 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $196,664 | 4 | 72.8% |
| Consulting Fee | $57,401 | 20 | 21.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,149 | 5 | 2.3% |
| Honoraria | $5,113 | 2 | 1.9% |
| Travel and Lodging | $2,548 | 12 | 0.9% |
| Food and Beverage | $2,431 | 30 | 0.9% |
Payments by Type
Research
$196,664
4 transactions
General
$73,641
69 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AI Therapeutics, Inc. | $187,213 | 3 | $0 (2020) |
| Seagen Inc. | $19,554 | 20 | $0 (2023) |
| Celgene Corporation | $11,654 | 11 | $0 (2023) |
| Kite Pharma, Inc. | $9,540 | 3 | $0 (2021) |
| ADC Therapeutics America, Inc. | $9,492 | 5 | $0 (2023) |
| LAM Therapeutics, Inc. | $9,450 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $4,036 | 4 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $3,513 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $3,306 | 4 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,655 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,790 | 8 | E.R. Squibb & Sons, L.L.C. ($3,306) |
| 2023 | $16,516 | 19 | Seagen Inc. ($12,321) |
| 2022 | $12,732 | 9 | Seagen Inc. ($7,233) |
| 2021 | $7,920 | 3 | Kite Pharma, Inc. ($7,120) |
| 2020 | $67,848 | 5 | AI Therapeutics, Inc. ($57,956) |
| 2019 | $79,289 | 7 | AI Therapeutics, Inc. ($70,624) |
| 2018 | $67,661 | 12 | AI Therapeutics, Inc. ($58,634) |
| 2017 | $12,548 | 10 | LAM Therapeutics, Inc. ($9,450) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $56.34 | General |
| Category: Oncology | ||||||
| 12/06/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $74.57 | General |
| Category: Oncology | ||||||
| 09/06/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,160.00 | General |
| Category: Oncology | ||||||
| 07/15/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $192.99 | General |
| Category: Oncology | ||||||
| 02/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $441.89 | General |
| 02/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $347.10 | General |
| 02/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $94.79 | General |
| 01/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,422.00 | General |
| 12/10/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $142.71 | General |
| 12/10/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $18.52 | General |
| 12/07/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 12/07/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $29.97 | General |
| 11/09/2023 | Seagen Inc. | ADCETRIS (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Consulting Fee | Cash or cash equivalent | $9,100.00 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $68.57 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $45.98 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $19.00 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $406.81 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $304.07 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $247.00 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $202.00 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $60.16 | General |
| Category: Oncology | ||||||
| 08/19/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $57.41 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LAM 002A-NHL-CLN01 | AI Therapeutics, Inc. | $128,580 | 2 |
| LAM 002A-NHL CLN01 | AI Therapeutics, Inc. | $58,634 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 374 | 954 | $424,900 | $102,761 |
| 2022 | 9 | 384 | 904 | $366,275 | $93,318 |
| 2021 | 9 | 343 | 835 | $271,845 | $101,586 |
| 2020 | 9 | 295 | 794 | $276,430 | $88,456 |
Total Patients
1,396
Total Services
3,487
Medicare Billing
$386,122
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 79 | 314 | $172,700 | $39,417 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 277 | $96,950 | $30,060 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 97 | 192 | $81,600 | $16,082 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 40 | 40 | $28,000 | $5,494 | 19.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 25 | $16,250 | $3,953 | 24.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 40 | $10,000 | $2,886 | 28.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 22 | 24 | $6,000 | $1,773 | 29.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 16 | $5,600 | $1,680 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 20 | 26 | $7,800 | $1,416 | 18.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 75 | 327 | $111,630 | $30,163 | 27.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 226 | $116,510 | $29,723 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 126 | $47,005 | $10,055 | 21.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 39 | 46 | $29,900 | $8,203 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 36 | 36 | $24,400 | $5,997 | 24.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 51 | $12,350 | $3,280 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 38 | 48 | $12,510 | $2,609 | 20.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 23 | 30 | $7,140 | $1,959 | 27.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 14 | $4,830 | $1,329 | 27.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 29 | 144 | $23,040 | $23,112 | 100.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 52 | 236 | $77,880 | $22,548 | 29.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 58 | 147 | $66,885 | $22,196 | 33.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 72 | 130 | $44,200 | $14,974 | 33.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 28 | $18,200 | $5,218 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 58 | $13,340 | $4,901 | 36.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $11,050 | $3,606 | 32.6% |
About Dr. Sarah Rutherford, M.D
Dr. Sarah Rutherford, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2009. The National Provider Identifier (NPI) number assigned to this provider is 1245467752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarah Rutherford, M.D has received a total of $270,304 in payments from pharmaceutical and medical device companies, with $5,790 received in 2024. These payments were reported across 73 transactions from 21 companies. The most common payment nature is "" ($196,664).
As a Medicare-enrolled provider, Rutherford has provided services to 1,396 Medicare beneficiaries, totaling 3,487 services with total Medicare billing of $386,122. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 06/11/2009
- Last Updated 07/19/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1245467752
Products in Payments
- ADCETRIS (Biological) $21,963
- Yescarta (Drug) $9,540
- CALQUENCE (Drug) $4,009
- XPOVIO (Drug) $3,513
- Revlimid (Drug) $3,080
- JCAR017 (Drug) $2,825
- IMBRUVICA (Drug) $2,775
- Doptelet (Drug) $2,500
- SUSTOL (Drug) $1,842
- VENCLEXTA (Biological) $388.57
- GAZYVA (Biological) $205.08
- Epkinly (Drug) $56.34
- VENCLEXTA (Drug) $37.29
- ELIGARD (Drug) $23.94
- Prolia (Biological) $15.67
- Aranesp (Biological) $15.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205